Novo Nordisk Shares Surge Following Strong Trial Results
Novo Nordisk shares surge Novo Nordisk shares surge over 2% during premarket trading. This rise came after Evercore ISI spotlighted the company’s presentation on its oral amycretin trial. The trial’s part C, which tested two dosing regimens—50 mg once daily and 50 mg twice daily—showed strong and consistent efficacy without plateauing. Placebo Group Shows Minor …
Novo Nordisk Shares Surge Following Strong Trial Results Read More »